Search

Infections in Hematology

The SWG on Infection in Hematology was founded in 2017 and follows four main goals:

Develop and share clinically useful tools: Many hematologists create checklists and pathways for quick and easy reference.

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

Membership

Boost your career, fast-track your development, and make new connections by joining a pioneering European hematology organization with global reach.

Read more

Genetic Predisposition to Blood Cancer (Rare diseases)

The objectives of the group are:

Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.

Read more

EHA-SWG Scientific Meeting on Pediatric Hematology 2022

On April 7-9, 2022 the EHA-SWG Scientific Meeting on Pediatric Hematology was successfully held at the NH Collection Vittorio Veneto hotel in Rome.

Read more

From Plans to Action: European Cancer Summit

From Plans to Action:  European Cancer Summit (Brussels-Hybrid, November 17-18, 2021) 
November 17- 18 marks the first anniversary of EHA’s membership to the European Cancer Organisation (ECO), as well as the event dates for the 2021 European Cancer Summit.

Read more

Meeting program

Friday, April 25 - EHA-Balkan Hematology Day 202509:00 - 10:10 CEST Opening remarks & special lecture

Welcome of participants
Dimitar Efremov (Italy)
Welcome and introduction of meeting program
Irina Panovska-Stavridis (North Macedonia)
EHA and History of Balkan Hematology Day
Gianluca Gaidano (Italy)
History of the Balkan Hematology…

Read more

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA-SWG Scientific Meeting on From aging hematopoietic stem cells to age-related diseases: opportunities for intervention.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more